1. The pathologic response rate was similar in the atezolizumab treatment group as compared to...
Read More
1. Median event-free survival in the liso-cel group was significantly greater than in the...
Read More
1. High tumour mutation burden levels were associated with improvements in objective response...
Read More
1. The rate of progression was 57% lower in the group receiving anal HSIL treatment as compared to...
Read More
1. Between 2015 and 2020, human papillomavirus vaccination (HPV) rates in the United States...
Read More
1. The circulating tumour DNA-guided approach was non-inferior to the standard clinicopathological...
Read More
1. In this systematic review and meta-analysis, medical cannabis and cannabinoids versus placebo...
Read More
1. Disease-free survival did not differ significantly between patient groups and overall survival...
Read More
1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher...
Read More
1. 5-year progression-free status was greatest in group 3 (triple therapy) and lowest in group 1...
Read More
1. Progression-free survival was longer for patients receiving tiragolumab with atezolizumab as...
Read More
1. The adebrelimab group had an improved overall survival, higher objective response rate and an...
Read More
Click to read this study in the Journal of Clinical Oncology.
Read More
Click to read this study in Journal of Clinical Oncology.
Read More
1. Complete clinical response at 6 months was similar in both the topical imiquimod and surgery...
Read More
1. The median progression free survival for all cancer-types was 2.8 months. 2. Most of the...
Read More
1. A combination of androgen deprivation therapy, docetaxel, and abiraterone (“triplet therapy”)...
Read More
1. Patients with resectable non-small cell lung cancer (NSCLC) receiving neoadjuvant nivolumab in...
Read More
